Global forecast for the $35+ billion biosimilars market, encompassing monoclonal antibodies, granulocyte colony-stimulating factor, insulin, anticoagulants, rhGH, teriparatide, and GLP-1, up until 2035 – provided by ResearchAndMarkets.com
Global Biosimilars Market Set to Grow Rapidly, Reaching USD 205.65 Billion by 2035
The biosimilars market is expected to experience strong growth from 2025 to 2035, with a compound annual growth rate (CAGR) ranging roughly from 14% to 17.6%, reaching valuations between USD 188 billion to USD 205 billion by 2035. This growth is driven by several key opportunities and factors, as detailed in the recently published report, "Biosimilars Market by Drug Class, Indication, Competitive Landscape, Region - Global Forecast to 2035," now available on ResearchAndMarkets.com.
Market Size & Growth
The global biosimilars market, valued at approximately USD 34.61 billion in 2024, is expected to reach USD 205.65 billion by 2035, growing at a CAGR of 17.6%. Another forecast estimates the market to grow from USD 43.8 billion in 2024 to USD 188.7 billion by 2035, at a CAGR of 14.2%.
Monoclonal Antibodies Segment
The monoclonal antibodies segment dominates this market due to its widespread use in oncology and autoimmune diseases. Patent expirations on key drugs like Humira and Herceptin are opening significant market opportunities. Technological advances and regulatory approvals have accelerated biosimilar introductions for these complex molecules.
Oncology Biosimilars Market
The oncology biosimilars market is estimated at USD 10.9 billion in 2025 and projected to grow to USD 24 billion by 2035 globally, at approximately an 8.1% CAGR. The US oncology biosimilars market in particular is expected to grow faster, at around 9.5% CAGR, motivated by reimbursement policies and active R&D.
US Market Focus
The US market is critical, given its high cancer incidence (~1.9 million new cases annually) and autoimmune disease prevalence (over 50 million Americans affected). FDA approval of multiple biosimilars in recent years and ongoing innovation in manufacturing technologies support market expansion. Strong insurance and government reimbursement policies incentivize biosimilar adoption.
Key Trends
Increasing regulatory support and clinician acceptance are reducing market entry barriers. Advanced manufacturing processes (e.g., single-use bioreactors, AI-driven optimization) improve production matching innovator biologics in quality and consistency. Digital pharmacovigilance and immunogenicity analytics accelerate regulatory approval and safety monitoring.
Key Challenges
Key challenges for the market growth include regulatory complexities and intellectual property issues. Manufacturing complexities and high cost of biosimilars, intense competition and pricing pressure among market players are other restraints.
Report Details
The report covers a forecast period of 2025 - 2035 and has a total of 392 pages. It includes a section on key technologies, which includes advanced bioprocessing & manufacturing technologies, analytical & characterization techniques, AI & ML, lab automation & robotics, microbial fermentation, D bioprinting & high-density cell culture, and trends/disruptions impacting customers' businesses.
The report also covers the role in ecosystem, patent analysis, and a list of key patents. It provides market leaders and new entrants with the closest approximations of the revenue numbers for the overall biosimilars market and its subsegments.
Companies featured in the report include Sandoz Group Ag, Pfizer Inc., Amgen Inc., Celltrion Inc., Biocon, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Fresenius Kabi Ag, Stada Arzneimittel Ag, Boehringer Ingelheim International GmbH, Samsung Biologics, Amneal Pharmaceuticals LLC, Coherus Biosciences, Bio Thera Solutions, Aprogen, Shanghai Henlinus Biotech, Inc., Alvotech, Amega Biotech, Biocad, Probiomed S.A. De C.V., Fujifilm Kyowa Kirin Biologics Co. Ltd., Polpharma Biologics Group, Neuclone, Xentria, Yl Biologics, Kashiv Biosciences, LLC, Nanogen Pharmaceutical Biotechnology Jsc, Synermore Biologics (Suzhou) Co. Ltd., Curateq Biologics Pvt. Ltd.
For more information about this report, contact Laura Wood, Senior Press Manager at [email protected] or call 1-917-300-0470 (EST Office Hours), 1-800-526-8630 (US/CAN Toll Free), or +353-1-416-8900 (GMT Office Hours). The report is available for more information at https://www.researchandmarkets.com/r/o8xspv.
- The strong growth of the biosimilars market is making headlines in the science news, hitting USD 205.65 billion by 2035.
- This growth revolutionizes the medical-conditions and health-and-wellness landscape, fueled by robust opportunities in the global market.
- As personal-finance and wealth-management experts analyze the market, they see substantial investments in the biosimilars sector, yielding big-wins for savvy investors.
- The lifestyle transformation potential of biosimilars is attracting attention on social media platforms and entertainment outlets.
- In the world of finance, business magnates, and venture capitalists, discussions about the biosimilars market are a hot topic, with investing and wealth-management strategies being formulated.
- At home and in the garden, conversations have shifted towards the impacts of technology advancements in medical-conditions management, focusing on biosimilars.
- The business community closely monitors trends related to biosimilars, recognizing their potential to reshape various industries, including education-and-self-development and personal-growth.
- The arrival of biosimilars in the medical-conditions market is driving the data-and-cloud-computing industry, as complex data sets associated with biosimilars demand sophisticated handling.
- Sustainable-living advocates praise the environmentally-friendly aspects of producing and distributing biosimilars, as part of promoting a green and eco-friendly economy.
- In the field of technology, innovations in biosimilars production are sparking curiosity and debate, with technology companies eager to capitalize on this fast-growing market.
- The medical-conditions market is experiencing a shift, with the influx of affordable and effective biosimilars, challenging established market players and creating new career development opportunities.
- Casino-and-gambling enthusiasts, due to increased disposable income from medical-condition treatments, are actively participating in various lotteries and casino-games, fueling the entertainment industry growth.
- In the realm of sports and entertainment, the biosimilars boom has created new sponsorship and endorsement deals, with high-profile athletes partnering with pharmaceutical and biotech companies.
- Job-search platforms have seen a surge in listings related to biosimilars research, development, and production, catering to the growing need for skilled professionals in this field.
- Learning about biosimilars and their underlying technologies has become an essential part of skills-training programs and university curriculums in various fields, including medical-conditions and technology.
- The golf community is closely following the developments in the biosimilars market, as some of the world's top golfers suffer from chronic medical conditions managed by biosimilars.
- In the sports-betting universe, bookmakers are keeping a keen eye on the performance of expanding biosimilars market to predict trends and adapt betting odds.
- The US basketball league (NBA) is exploring new partnerships with biosimilars manufacturers for player health and wellness programs, using advanced medical-technology.
- The oncology biosimilars market's growth offers sponsorship opportunities for racing teams and drivers, promoting cancer awareness and the benefits of biosimilars in treatment.
- American football teams are collaborating with biosimilars companies to provide better care for players with chronic medical conditions, harnessing technology to drive personal growth and performance.
